Does Botox cause hair loss? It is a question raised with increasing frequency by patients undergoing cosmetic botulinum toxin treatments in the UK. Botulinum toxin type A — available under brands such as Vistabel, Azzalure, and Bocouture — is a prescription-only medicine used for facial lines, hyperhidrosis, and chronic migraine, among other licensed indications. Whilst scalp-adjacent injections have prompted concern about hair thinning, current pharmacovigilance data do not support a causal link. This article examines the evidence, outlines recognised side effects, and explains when to seek medical advice.

Can Botox Cause Hair Loss?

Alopecia is not listed as a recognised adverse effect in the UK SmPCs for licensed botulinum toxin products, and current pharmacovigilance data do not support a causal link between standard cosmetic injections and hair loss.

Experiencing these side effects? Our pharmacists can help you navigate them →

Botulinum toxin type A is one of the most widely used cosmetic and medical treatments in the UK. It works by temporarily blocking the release of acetylcholine at neuromuscular junctions, preventing muscle contraction. Several botulinum toxin type A products are licensed in the UK for different indications: aesthetic products such as Vistabel, Azzalure, and Bocouture are licensed for the temporary improvement of facial lines, whilst Botox (the therapeutic formulation) holds licences for conditions including hyperhidrosis (excessive sweating), chronic migraine, and certain muscle spasticity conditions. These products are not interchangeable, and their licensed indications, doses, and safety profiles differ. All botulinum toxin products are prescription-only medicines and must be administered by appropriately qualified prescribers working within a regulated clinical environment.

A question that arises with some regularity among patients is whether botulinum toxin injections can contribute to hair loss or thinning. This concern is understandable, given that the scalp and surrounding areas are sometimes treated — particularly in procedures targeting the forehead or temples, or in techniques that inject botulinum toxin directly into the scalp. It is important to note that scalp injections for hair growth or craniofacial hyperhidrosis are not within the licensed indications of any UK-approved botulinum toxin product and should be considered off-label and investigational.

Alopecia is not listed as a common or expected adverse effect in the UK Summaries of Product Characteristics (SmPCs) for licensed botulinum toxin products; however, patients should consult the specific SmPC for the product they have received for full details. Current pharmacovigilance data do not support a causal link between standard cosmetic botulinum toxin injections and hair loss, though individual patient experiences vary and understanding the broader context is important for anyone concerned about changes to their hair following treatment.

What the Evidence Says About Botox and Hair Thinning

No robust clinical trial or systematic review has demonstrated that botulinum toxin causes hair loss; small studies have actually explored it as a potential treatment for androgenetic alopecia, though this remains investigational.

Not sure if this is normal? Chat with one of our pharmacists →

The scientific literature on botulinum toxin and hair loss is limited and, in some respects, points in the opposite direction to patient concerns. Several small-scale pilot studies and case reports have investigated botulinum toxin as a potential treatment for androgenetic alopecia (pattern hair loss). The proposed mechanism in these studies suggests that by relaxing scalp musculature and reducing tension, botulinum toxin may improve blood flow to hair follicles, potentially supporting follicular health. However, this mechanistic rationale remains hypothetical, the studies involved are small and methodologically limited, and this approach is not part of any NICE-approved or NHS-recommended treatment pathway.

In terms of botulinum toxin causing hair loss, no robust clinical trial or systematic review has demonstrated a direct causal relationship, and published pharmacovigilance data do not show a recognised signal for alopecia with these products. There are isolated anecdotal reports of individuals noticing increased hair shedding after botulinum toxin treatments, but these have not been substantiated in peer-reviewed literature. It is important to note that absence of evidence is not definitive proof of no risk; however, current data — including MHRA pharmacovigilance records — do not indicate a causal association. It is also worth noting that:

• Correlation does not equal causation — hair loss may coincide with treatment for entirely unrelated reasons.

• Many patients receiving cosmetic botulinum toxin are in age groups where natural hair thinning is common.

• Stress associated with any medical or cosmetic procedure can itself trigger a temporary form of hair shedding known as telogen effluvium.

Until larger, well-controlled studies are conducted, it would be premature to conclude that botulinum toxin injections cause hair loss. Patients should be reassured that current evidence does not support this association, whilst acknowledging that individual responses to any medical treatment can vary.

Known Side Effects of Botulinum Toxin Recognised by the MHRA

MHRA-recognised side effects of botulinum toxin include injection site reactions, headache, ptosis, and flu-like symptoms; alopecia is not listed as a common adverse effect in licensed product SmPCs.

The MHRA regulates botulinum toxin products in the UK, and the approved SmPC for each licensed preparation outlines a well-characterised side-effect profile. Aesthetic products licensed for facial lines include Vistabel and Bocouture (onabotulinumtoxinA and incobotulinumtoxinA respectively) and Azzalure (abobotulinumtoxinA). Alopecia is not listed as a common or expected adverse effect in these SmPCs; patients should refer to the SmPC for the specific product they have received for a complete list of adverse reactions and their reported frequencies.

The known and commonly reported side effects of botulinum toxin injections include:

• Injection site reactions — bruising, redness, swelling, and temporary discomfort

• Headache — particularly following forehead or glabellar injections

• Ptosis (drooping eyelid) — a well-recognised complication if the toxin migrates to the levator palpebrae muscle

• Flu-like symptoms — mild and transient in most cases

• Dry eyes or excessive tearing — when treating periorbital areas

• Neck weakness or dysphagia — more relevant to therapeutic doses used in cervical dystonia

An important class warning applies to all botulinum toxin products: the toxin may spread beyond the injection site, potentially causing muscle weakness, dysphagia, aspiration, or respiratory compromise. This risk is greatest at higher therapeutic doses but should be considered in all clinical contexts. Hypersensitivity reactions, including anaphylaxis, have also been reported. Particular caution is required in patients with pre-existing neuromuscular disorders. These risks are detailed in the MHRA Drug Safety Update on botulinum toxin products and in individual SmPCs.

Botulinum toxin injected into the scalp — a technique sometimes offered outside of licensed indications — carries a different and less well-characterised risk profile compared with standard facial cosmetic use. Such treatments are off-label and should be approached with caution. In England, practitioners offering non-surgical cosmetic procedures involving prescription-only medicines, including botulinum toxin, are subject to licensing requirements introduced under the Health and Care Act 2022; patients should verify that their practitioner is appropriately qualified and working within a regulated clinical environment.

Patients and practitioners are encouraged to report any unexpected adverse reactions via the MHRA Yellow Card scheme (yellowcard.mhra.gov.uk), which helps regulators monitor the safety of medicines and medical procedures across the UK.

Other Common Causes of Hair Loss to Consider

Hair loss coinciding with a botulinum toxin treatment is most likely due to unrelated causes such as telogen effluvium, androgenetic alopecia, thyroid dysfunction, or nutritional deficiencies.

When a patient notices hair thinning or shedding around the time of a botulinum toxin treatment, it is clinically important to consider the many well-established causes of hair loss that may be coincidental rather than treatment-related. Hair loss is extremely common in the UK, affecting a significant proportion of both men and women at some point in their lives (NHS, 2023).

Common causes to consider include:

• Telogen effluvium — a temporary, diffuse shedding triggered by physical or emotional stress, illness, surgery, significant weight loss, or hormonal changes. Symptoms typically appear 2–3 months after the triggering event, which can make the condition appear linked to a recent procedure. Postpartum telogen effluvium, occurring after childbirth, is a particularly common and well-recognised variant.

• Androgenetic alopecia — the most common form of hair loss in both men and women, driven by genetic and hormonal factors.

• Thyroid dysfunction — both hypothyroidism and hyperthyroidism can cause diffuse hair thinning and should be excluded with appropriate blood tests.

• Nutritional deficiencies — low ferritin (iron stores) and inadequate protein intake are frequently implicated. Vitamin D deficiency has been associated with some forms of hair loss, though the evidence for a causal relationship is mixed; testing and supplementation should be guided by clinical assessment.

• Traction alopecia — hair loss caused by prolonged tension on the hair shaft from certain hairstyles; this is preventable if identified early.

• Tinea capitis — a fungal infection of the scalp, particularly common in children, which can cause patchy hair loss with scaling or inflammation and requires prompt antifungal treatment.

• Alopecia areata — an autoimmune condition causing patchy hair loss.

• Scarring alopecias (e.g., lichen planopilaris, frontal fibrosing alopecia) — a group of conditions in which inflammation destroys hair follicles, leading to permanent hair loss if not treated promptly. These require urgent dermatological assessment.

• Medications — a wide range of drugs, including certain antihypertensives, anticoagulants, and hormonal contraceptives, are associated with hair shedding.

A thorough medical history and appropriate investigations — guided by NICE Clinical Knowledge Summaries on alopecia — are essential before attributing hair loss to any cosmetic procedure. Jumping to conclusions without proper evaluation risks missing a treatable underlying cause.

When to Speak to a GP or Dermatologist

See your GP if you experience sudden, patchy, or rapidly progressing hair loss, especially if accompanied by scalp changes, systemic symptoms, or significant distress, so that treatable underlying causes can be investigated.

If you have noticed hair thinning or increased shedding — whether or not it follows a cosmetic procedure such as a botulinum toxin injection — it is advisable to seek a professional medical opinion rather than self-diagnosing or attributing the change to a specific treatment without evidence.

You should contact your GP if you notice:

• Sudden or rapid hair loss over a short period

• Patchy hair loss or bald spots

• Hair loss accompanied by other symptoms such as fatigue, weight changes, skin changes, or irregular periods

• Significant scalp changes including redness, scaling, or scarring

• Hair loss that is causing psychological distress or affecting quality of life

Seek prompt assessment if you notice a painful or inflamed scalp, pustules, or any signs of scarring at the hairline or elsewhere on the scalp, as scarring alopecias can cause permanent hair loss if not treated early.

Your GP can arrange initial investigations, which typically include blood tests to assess thyroid function (TSH), full blood count, and ferritin levels. Hormonal testing (for example, androgen levels) is not routine but may be appropriate in women presenting with features of hyperandrogenism such as hirsutism or irregular periods, in line with NICE Clinical Knowledge Summaries guidance. If an underlying cause is identified, treatment can be directed accordingly. For more complex or persistent cases, referral to an NHS dermatologist is the recommended pathway. Trichologists — specialists in hair and scalp conditions — can provide adjunctive advice, but it is important to be aware that the title 'trichologist' is not a protected medical designation and trichologists are not medically regulated in the same way as NHS clinicians.

In summary, whilst the question of whether botulinum toxin causes hair loss is understandable, current evidence does not support a causal link. Maintaining perspective, seeking professional advice, and investigating other potential causes remain the most clinically sound approach for anyone experiencing unexpected hair changes.

Frequently Asked Questions